Brief: Seelos Therapeutics Doses First Patients In An Ethnobridging Study With SLS-002

Seelos Therapeutics

06/02/2023 16:57

Feb 6 (Reuters) - Seelos Therapeutics Inc  SEEL.O :
    * SEELOS THERAPEUTICS DOSES FIRST PATIENTS IN AN
ETHNOBRIDGING
STUDY WITH SLS-002 (INTRANASAL RACEMIC KETAMINE)
    * SEELOS -CONDUCTING PHASE I ETHNOBRIDGING STUDY IN HEALTHY
JAPANESE, NON-ASIAN SUBJECTS TO EVALUATE SAFETY, PHARMACOKINETIC
PROFILES OF SLS-002

Source text for Eikon:  ID:nPn14NTyKa 
Further company coverage:  SEEL.O 
 ((Reuters.Briefs@thomsonreuters.com;))